Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Каталог · ЕАЭС

Клинические исследования и проекты

UCB Pharma · найдено 23

UCB Pharma
Ищем по всем вариантам написания в реестрах, по-русски и по-английски. Спонсор или разработчик.
Статус
Что исследуют
Источник
Фаза
Страна
Участники
Кто может участвовать По критериям ClinicalTrials.gov. Исследования, где реестр возраст и пол не указывает, тоже показываются. Возраст и пол нигде не сохраняются.
Сбросить
23 исследования
Завершено Фаза III Беларусь
Certolizumab Pegol (CDP870) · UCB Pharma

A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed 4-weekly), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Completed Studies CDP870-031 or CDP870-032

596 участников во всех странах ClinicalTrials.gov C87033
Завершено Фаза III Беларусь
Certolizumab Pegol (CDP870) · UCB Pharma

A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Re-exposure After a Variable Interval and Subsequent Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed at Weeks 0, 2 and 4 Then Every 4 Weeks), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Been Withdrawn From Studies CDP870-031 or CDP870-032 Due to an Exacerbation of Crohn's Disease.

310 участников во всех странах ClinicalTrials.gov C87034
Завершено Фаза III Россия
Certolizumab Pegol · UCB Pharma

A Phase III Multi-center, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Liquid Certolizumab Pegol as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and in the Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Participated in Study CDP870-050

567 участников во всех странах ClinicalTrials.gov C87051
Завершено Фаза III Россия
Brivaracetam (ucb 34714) · UCB Pharma

An Open-label, Multicenter, Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy

853 участника во всех странах ClinicalTrials.gov N01125
Завершено Фаза III Россия
certolizumab pegol (CDP870, CZP) · UCB Pharma

Phase IIIb, Multinational, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-Tumor Necrosis Factor(TNF)-Alpha Monoclonal Antibody, Administered in Subjects With Moderately to Severely Active Crohn's Disease.

439 участников во всех странах ClinicalTrials.gov C87085
Завершено Фаза II Россия
Carboplatin; Paclitaxel; CDP791 10mg/kg; CDP791 20mg/kg · UCB Pharma

A Two-Part, Open Label Phase II Trial: Part One, Dose Escalation Safety; Part Two, Randomized/Comparing CDP791 Plus Carboplatin/Paclitaxel With Carboplatin/Paclitaxel Alone in Subjects With Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

165 участников во всех странах ClinicalTrials.gov C79102
Завершено Фаза III Россия
Placebo; Brivaracetam · UCB Pharma

An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (≥ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.

480 участников во всех странах ClinicalTrials.gov N01254
Прекращено Россия
RA0091 · UCB Pharma

Observational Study to Evaluate the Safety and Effectiveness of Cimzia in Rheumatoid Arthritis and Crohn's Disease Patients When Using a Comprehensive Program of Tuberculosis Screening and Monitoring

199 участников во всех странах ClinicalTrials.gov RA0091
Завершено Фаза III Россия
levetiracetam (LEV) · UCB Pharma

A Multi-Center, Open-Label, Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures.

255 участников во всех странах ClinicalTrials.gov N01148
Завершено Фаза III Россия
BRV 2.5 mg; BRV 25 mg; BRV 50 mg · UCB Pharma

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥ 16 Years) With Genetically Ascertained Unverricht-Lundborg Disease

56 участников во всех странах ClinicalTrials.gov N01236
Завершено Фаза III Россия
Certolizumab Pegol · UCB Pharma

A Phase III Multi-centre, Open-label, follow-on Study to CDP870-027, to Assess the Efficacy and Safety of Lyophilized CDP870 an Engineered Human Anti-TNF PEG Conjugate, as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis

857 участников во всех странах ClinicalTrials.gov C87028
Завершено Фаза IV Россия
Lacosamide · UCB Pharma

An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures

461 участник во всех странах ClinicalTrials.gov SP0954
Завершено Фаза III Россия
Certolizumab Pegol · UCB Pharma

A Phase III Multi-center, Double-blind, Placebo-controlled, Parallel Group 24-Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate.

590 участников во всех странах ClinicalTrials.gov C87050
Завершено Фаза III Россия
Levetiracetam · UCB Pharma

A Double-Blind, Randomized, Multicenter, Placebo-controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/Day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age From 1 Month to Less Than 4 Years of Age

116 участников во всех странах ClinicalTrials.gov N01009
Завершено Фаза III Россия
Lacosamide · UCB Pharma

A Multi-center, Open-label, follow-on Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy Including a Double-blind, Randomized Time Point Withdrawal Subtrial.

621 участник во всех странах ClinicalTrials.gov SP0746
Завершено Фаза III Россия
Certolizumab pegol (CDP870) · UCB Pharma

A Phase III Multicentre, Double Blind, Placebo-controlled, Parallel Group 52-week Study to Assess the Efficacy and Safety of 2 Dose Regimens of Lyophilised CDP870 as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate

950 участников во всех странах ClinicalTrials.gov C87027
Завершено Фаза III Россия
Certolizumab Pegol (CDP870) · UCB Pharma

A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed 4-weekly), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Completed Studies CDP870-031 or CDP870-032

596 участников во всех странах ClinicalTrials.gov C87033
Завершено Фаза III Россия
Keppra XR; Keppra XR · UCB Pharma

A Multi-center, Double-blind, Historical Control, Randomized Conversion to Monotherapy Study With Keppra XR for Treatment of Partial Onset Seizures

228 участников во всех странах ClinicalTrials.gov N01280
Завершено Фаза III Россия
Levetiracetam; Carbamazepine Controlled Release (CBZ-CR); Valproate Extended Release · UCB Pharma

A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.

1 701 участник во всех странах ClinicalTrials.gov N01175
Завершено Фаза III Россия
Lacosamide · UCB Pharma

An International Open-label Extension Trial to Determine Safety and Efficacy of Long-term Oral Lacosamide (SPM 927) in Patients With Partial Seizures

376 участников во всех странах ClinicalTrials.gov SP0774

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.